The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Beta Bionics, Inc. BBNX recently entered into a strategic agreement with Abbott Laboratories ABT to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's upcoming ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options ...
For the quarter ended September 2025, Beta Bionics, Inc. (BBNX Quick Quote BBNX - Free Report) reported revenue of $27.25 million, representing no change compared to the same period last year. EPS ...
In recent trading, shares of Beta Bionics Inc (Symbol: BBNX) have crossed above the average analyst 12-month target price of $23.44, changing hands for $25.00/share. When a stock reaches the target an ...
Feider stated, "We expect to generate $130 million to $135 million of revenue in 2026. On our channel mix, we expect 36% to 38% of our new patient starts to be reimbursed through the pharmacy channel.
Beta Bionics, Inc. BBNX shares rallied 10.3% in the last trading session to close at $13.02. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Beta Bionics Inc. Annual stock financials by MarketWatch. View the latest BBNX financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results